Performance of the HAS-BLED, ORBIT, and ATRIA Bleeding Risk Scores on a Cohort of 399 344 Hospitalized Patients With Atrial Fibrillation and Cancer: Data From the French National Hospital Discharge Database.
ATRIA
HAS‐BLED
ORBIT
atrial fibrillation
bleeding
cancer
intracranial hemorrhage
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
06 12 2022
06 12 2022
Historique:
pubmed:
30
11
2022
medline:
15
12
2022
entrez:
29
11
2022
Statut:
ppublish
Résumé
Background The association between cancer types and specific bleeding events in patients with atrial fibrillation has been scarcely investigated. Also, the performance of bleeding risk scores in this high-risk subgroup of patients is unclear. We investigated the rate of any bleeding, intracranial hemorrhage, major bleeding, and gastrointestinal bleeding according to cancer types in patients with atrial fibrillation. We also tested the predictive value of HAS-BLED, ATRIA, and ORBIT bleeding risk scores. Methods and Results Observational retrospective cohort study including hospitalized patients with atrial fibrillation and cancer from the French National Hospital Discharge Database (Programme de Medicalisation des Systemes d'Information) from January 2010 to December 2019. Major bleeding was defined according to Bleeding Academic Research Consortium definitions. Patients with HAS-BLED ≥3, ATRIA ≥5, or ORBIT ≥4 were classified as at high bleeding risk. Receiver operating characteristic analysis for each score against any bleeding, major bleeding, gastrointestinal bleeding, and intracranial hemorrhage was performed. Areas under the curve (AUCs) were then compared. We included 399 344 patients. Mean age was 77.9±10.2 years, and 63.2% were men. The highest intracranial hemorrhage rates were found in leukemia (1.89%/year), myeloma (1.52%/year), lymphoma and liver (1.45%/year), and pancreas cancer (1.41%/year). Receiver operating characteristic analysis showed that ORBIT score predicted best for any bleeding. In addition, ORBIT score ≥4 had the highest predictivity for major bleeding (AUC, 0.805), followed by HAS-BLED ≥3 and ATRIA ≥5 (AUCs, 0.716 and 0.700, respectively). HAS-BLED and ORBIT performed best for intracranial hemorrhage (AUCs, 0.744 and 0.742 for continuous scores, respectively), better than ATRIA (AUC, 0.635). For gastrointestinal bleeding, ORBIT ≥4 had the highest predictivity (AUC, 0.756), followed by the HAS-BLED ≥3 (AUC, 0.702) and ATRIA ≥5 (AUC, 0.662). Conclusions Some cancer types carry a greater bleeding risk in patients with atrial fibrillation. The identification and management of modifiable bleeding risk factors is crucial in these patients, as well as to flag up high bleeding risk patients for early review and follow-up.
Identifiants
pubmed: 36444864
doi: 10.1161/JAHA.121.026388
pmc: PMC9851457
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e026388Références
J Am Heart Assoc. 2018 Aug 21;7(16):e008987
pubmed: 30369307
Stroke. 2014 May;45(5):1304-12
pubmed: 24743444
Blood Rev. 2019 May;35:59-67
pubmed: 30928168
J Am Heart Assoc. 2019 Jul 2;8(13):e012546
pubmed: 31234697
Med Decis Making. 2006 Nov-Dec;26(6):565-74
pubmed: 17099194
Am J Med. 2018 May;131(5):574.e13-574.e27
pubmed: 29274754
Eur Heart J. 2015 Dec 7;36(46):3258-64
pubmed: 26424865
J Thromb Haemost. 2016 Sep;14(9):1711-4
pubmed: 27296528
Clin Res Cardiol. 2021 Sep;110(9):1431-1438
pubmed: 33507390
J Am Coll Cardiol. 2012 Aug 28;60(9):861-7
pubmed: 22858389
Antioxid Redox Signal. 2017 Nov 10;27(14):1083-1124
pubmed: 28816059
Circulation. 2011 Jun 14;123(23):2736-47
pubmed: 21670242
J Am Heart Assoc. 2016 Mar 08;5(3):e002197
pubmed: 26955859
Eur J Prev Cardiol. 2018 Apr;25(6):651-658
pubmed: 29482441
BMC Med Inform Decis Mak. 2008 Nov 26;8:53
pubmed: 19036144
Circulation. 2011 May 31;123(21):2363-72
pubmed: 21576658
J Am Coll Cardiol. 2013 Dec 10;62(23):2199-204
pubmed: 24055744
Chest. 2010 Nov;138(5):1093-100
pubmed: 20299623
Cancer. 2021 Jun 15;127(12):2122-2129
pubmed: 33631041
Ann Med. 2020 Nov;52(7):413-422
pubmed: 32795156
Am J Cardiol. 2017 Nov 1;120(9):1549-1556
pubmed: 28844514
Open Heart. 2015 Dec 01;2(1):e000290
pubmed: 26688739
J Am Coll Cardiol. 2016 Dec 13;68(23):2508-2521
pubmed: 27931607
Thromb Haemost. 2018 Dec;118(12):2171-2187
pubmed: 30376678
Eur Heart J. 2021 Feb 1;42(5):373-498
pubmed: 32860505
Prog Cardiovasc Dis. 2021 May-Jun;66:28-36
pubmed: 33915139
J Clin Med. 2021 Oct 08;10(19):
pubmed: 34640629
Eur Heart J Qual Care Clin Outcomes. 2019 Apr 1;5(2):145-152
pubmed: 30219887
Am J Med. 2017 Dec;130(12):1440-1448.e1
pubmed: 28739198
J Thromb Haemost. 2020 Apr;18(4):791-801
pubmed: 31782613
J Am Coll Cardiol. 2011 Jul 19;58(4):395-401
pubmed: 21757117
Int J Cancer. 2020 Dec 15;147(12):3424-3430
pubmed: 32588421
J Am Coll Cardiol. 2020 Apr 14;75(14):1689-1713
pubmed: 32273035
Eur Heart J Qual Care Clin Outcomes. 2022 Oct 26;8(7):778-786
pubmed: 34555148
Int J Clin Pract. 2021 May;75(5):e14042
pubmed: 33486858
Neurology. 2020 Nov 17;95(20):e2736-e2745
pubmed: 32917797
Am J Med. 2020 Oct;133(10):1195-1202.e2
pubmed: 32289310